drugset / Trial / NCT02852083
A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II, multicentre, open-label, randomized, and controlled study, evaluating the efficacy and safety of combined modularized treatment of treosulfan, pioglitazone and clarithromycin in patients with with squamous and non- squamous cell lung cancer, respectively after platin failure.
Timeline
- Start
- 2016-01
- Primary completion
- 2019-07
- Completion
- 2020-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 250 mg | Oral |
| Comparator | Nivolumab | Monoclonal antibody | 3 mg/kg | Oral |
| Subject | Pioglitazone | Small molecule | 25 mg | Oral |
| Subject | Treosulfan | Small molecule | 250 mg | Oral |